Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease

Article Abstract:

Hodgkin's disease is characterized by tumor growth in the lymph nodes, and enlargement of the spleen and liver, and is often accompanied by anemia (low numbers of red blood cells) and fever. The standard treatments are radiation therapy, chemotherapy, or a combination of both. A recent study conducted by the European Organization for Research and Treatment of Cancer (EORTC) estimated 6 percent mortality due to Hodgkin's disease. The erythrocyte sedimentation rate (ESR) is a diagnostic blood test that has been shown to be a valuable predictor of relapse and sudden death caused by this disease. A higher than normal (elevated) ESR is associated with inflammation, infection or red blood cell damage. To evaluate the effectiveness of ESR as a predictor of relapse and survival, the ESR was determined before and after chemotherapy or radiation therapy in 772 patients with early-stage Hodgkin's disease. The findings indicate that an elevated ESR was the most predictive factor of mortality. Following treatment, patients who had elevated ESRs were seven times more likely to die from their disease than patients who had normal ESRs, regardless of the type of therapy. The second most important predictor of survival was early relapse; the risk of early relapse was greater for patients who had elevated ESRs after being treated. Patients with both early relapse and normal ESRs were 4 times more likely to die from their disease, and patients with both early relapse and elevated ESRs were 10 times more likely to die than patients who did not have early relapse. An elevated ESR after treatment for early-stage Hodgkin's disease is predictive of early relapse and a poor outcome. (Consumer Summary produced by Reliance Medical Information, Inc.)

Usage, Mortality, Patient outcomes, Erythrocyte sedimentation rate

---

Involved-field radiotherapy for advanced Hodgkin's lymphoma

Article Abstract:

Radiation treatment may not benefit patients with Hodgkin's disease who go into remission after taking chemotherapy, according to a study of 421 patients. However, patients who go into a partial remission may benefit. The patients in this study all received six to eight cycles of a chemotherapy regimen called MOPP-ABV.

Evaluation

---

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

Article Abstract:

The results from trials of patients with favorable prognostic features of Hodgkin's disease are reported. Chemotherapy plus involved-field radiotherapy was found to be superior to subtotal nodal radiotherapy as standard therapy while limited chemotherapy was effective for unfavorable patients.

United States, Health aspects, Complications and side effects, Comparative analysis, Cancer, Chemotherapy, Chemotherapy, Combination, Combination chemotherapy, Clinical report

Similar abstracts:

• Abstracts: Racial differences in the relation between blood pressure and insulin resistance. Where all the glucose doesn't go in non-insulin-dependent diabetes mellitus
• Abstracts: Scleroderma and survival. Epidemiology of scleroderma. Mortality from scleroderma in England and Wales 1968-1985
• Abstracts: A standard heparin nomogram for the management of heparin therapy. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.